Arbli Suspension
Product Images NDC 83245-053

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Arbli (NDC 83245-053). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Scienture Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (Carton Label)

Label for ARBLI oral suspension (losartan potassium) 10 mg/mL by Scienture LLC. The label includes the proprietary name, generic name, dosage form, strength, and net contents (5.5 fl oz / 165 mL). Storage instructions, manufacturer and distributor information, and a barcode are also visible on the label.*

FDA Label Image

Container (Container Label)

The label for Tradename losartan potassium oral suspension displays the strength as 10 mg/mL in a 5.5 fl oz (165 mL) container. It includes storage instructions at 20 to 25°C with allowed excursions, cautions to keep the container tightly closed and out of reach of children, and manufacturer details for Scienture Inc., Hauppauge, NY. The label shows the NDC 83245-053-06 and includes a barcode.*

FDA Label Image

Figureone (Figure1)

A line graph comparing the percentage of patients with a primary endpoint over 66 study months for Atenolol (dotted line) and Losartan (solid line). The graph shows adjusted risk reduction of 13% with a p-value of 0.021, with the x-axis labeled 'Study Month' and the y-axis labeled '% patients with primary endpoint.'*

FDA Label Image

Figuretwo (Figure2)

A line chart showing the percentage of patients with fatal or non-fatal stroke over study months ranging from 0 to 66. Two lines compare the drugs atenolol (dotted line) and losartan (solid line). The chart indicates an adjusted risk reduction of 25% with losartan, with a significance level p=0.001.*

FDA Label Image

Figurethree (Figure3)

A forest plot chart comparing the hazard ratios and event rates of Losartan and Atenolol across various patient demographics and conditions for primary composite and stroke (fatal/non-fatal) outcomes. The chart includes data categories such as age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD), illustrating event rates and confidence intervals for each subgroup.*

FDA Label Image

Figurefour (Figure4)

A line graph showing the percentage of patients with an event over 48 months, comparing losartan versus placebo. The graph indicates a risk reduction of 16.1% with losartan, with p=0.022, illustrating the cumulative event rates over time for both treatments.*

FDA Label Image

Structuralformula (Structural Formula)

Chemical structure diagram of losartan potassium, showing its molecular components and bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.